Key Details
Price
$8.74Annual ROE
-74.63%Beta
1.80Events Calendar
Next earnings date:
Feb 26, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 9, 2020Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Bezuclastinib is COGT's main value driver, currently undergoing 3 late-stage trials for SM and GIST. COGT's SUMMIT Part 2 for nonAdvSM will give us decisive data in July 2025, which I consider its main catalyst this year. Bezuclastinib could target an aggregate TAM of up to $2.5 billion across NonAdvSM, AdvSM, and GIST, which dwarves its current market cap.
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass.
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:
FAQ
- What is the ticker symbol for Cogent Biosciences?
- Does Cogent Biosciences pay dividends?
- What sector is Cogent Biosciences in?
- What industry is Cogent Biosciences in?
- What country is Cogent Biosciences based in?
- When did Cogent Biosciences go public?
- Is Cogent Biosciences in the S&P 500?
- Is Cogent Biosciences in the NASDAQ 100?
- Is Cogent Biosciences in the Dow Jones?
- When was Cogent Biosciences's last earnings report?
- When does Cogent Biosciences report earnings?
- Should I buy Cogent Biosciences stock now?